Randomized, placebo-controlled trial reveals the impact of dose and timing of <i>Bifidobacterium infantis</i> probiotic supplementation on breastfed infants' gut microbiome.

ABSTRACT: A dysfunctional gut microbiome has become increasingly common in infants born in high-income countries as Bifidobacterium strains no longer dominate the gut microbiome. Probiotics containing Bifidobacterium infantis have been used in breastfed newborns to successfully restore the gut microbiome; however, no studies to date have demonstrated this effect in older breastfed infants whose gut microbiomes are transitioning toward stability and maturity. This is a 9-week randomized controlled trial wherein 2-4 months old exclusively breastfed infants (n = 40) received 0 CFU/day B. infantis EVC001 (placebo), 4.0 × 10⁹ CFU/day B. infantis EVC001 (low), 8.0 × 10⁹ CFU/day B. infantis EVC001 (medium), or 1.8 × 10¹⁰ CFU/day

SUBMITTER: O'Brien CE 

PROVIDER: S-EPMC12838401 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature